SLNO Projected Dividend Yield
Com Par/Soleno Therapeutics Inc ( NASDAQ : SLNO )Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. 21 YEAR PERFORMANCE RESULTS |
SLNO Dividend History Detail SLNO Dividend News SLNO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |